83 FR 40775 - Meeting of the National Vaccine Advisory Committee

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Federal Register Volume 83, Issue 159 (August 16, 2018)

Page Range40775-40776
FR Document2018-17618

As stipulated by the Federal Advisory Committee Act, the Department of Health and Human Services is hereby giving notice that a meeting is scheduled to be held for the National Vaccine Advisory Committee (NVAC). The meeting will be open to the public; public comment sessions will be held during the meeting.

Federal Register, Volume 83 Issue 159 (Thursday, August 16, 2018)
[Federal Register Volume 83, Number 159 (Thursday, August 16, 2018)]
[Notices]
[Pages 40775-40776]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-17618]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES


Meeting of the National Vaccine Advisory Committee

AGENCY: National Vaccine Program Office, Office of the Assistant 
Secretary for Health, Office of the Secretary, Department of Health and 
Human Services.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: As stipulated by the Federal Advisory Committee Act, the 
Department of Health and Human Services is hereby giving notice that a 
meeting is scheduled to be held for the National Vaccine Advisory 
Committee (NVAC). The meeting will be open to the public; public 
comment sessions will be held during the meeting.

DATES: The meeting will be held on September 12 and 13, 2018. The 
meeting times and agenda will be posted on the NVAC website at http://www.hhs.gov/nvpo/nvac/meetings/index.html as soon as they become 
available.

ADDRESSES: U.S. Department of Health and Human Services, Hubert H. 
Humphrey Building, Room 800, 200 Independence Avenue SW, Washington, DC 
20201. The meeting can also be accessed through a live webcast on both 
days of the meeting. For more information, visit http://www.hhs.gov/nvpo/nvac/meetings/index.html.
    Pre-registration is required for members of the public who wish to 
attend the meeting and who wish to participate in a public comment 
session. Individuals who wish to attend the meeting and/or participate 
in a public comment session should register at http://www.hhs.gov/nvpo/nvac/meetings/index.html. Participants may also register by emailing 
[email protected] or by calling (202) 690-5566 and providing their name, 
organization, and email address.

FOR FURTHER INFORMATION CONTACT: Ann Aikin, Acting Designated Federal 
Officer, National Vaccine Program Office, U.S. Department of Health and 
Human Services, Room 715H, Hubert H. Humphrey Building, 200 
Independence Avenue SW, Washington, DC 20201. Phone: (202) 690-5566; 
email: [email protected].

SUPPLEMENTARY INFORMATION: Pursuant to Section 2101 of the Public 
Health Service Act (42 U.S.C. 300aa-1), the Secretary of Health and 
Human Services was mandated to establish the National Vaccine Program 
to achieve optimal prevention of human infectious diseases through 
immunization and to achieve optimal prevention against adverse 
reactions to vaccines. The NVAC was established to provide advice and 
make recommendations to the Director of the National Vaccine Program on 
matters related to the Program's responsibilities. The Assistant 
Secretary for Health serves as Director of the National Vaccine 
Program. During the September 2018 NVAC meeting, sessions will consist 
of presentations on valuing vaccines, including presentations on the 
role of vaccines in combatting antibiotic resistance; vaccine 
innovation, including presentations on financing, new technologies, and 
development of new vaccines; lessons from the field, with focus on 
Ebola and the new Shingles vaccine; and a session on HPV vaccination 
for cancer prevention. Please note that agenda items will be related to 
the charge of the Committee and are subject to change as priorities 
dictate. Information on the final meeting agenda will be posted prior 
to the meeting on the NVAC website: http://www.hhs.gov/nvpo/nvac/index.html.
    Public attendance at the meeting is limited to the available space. 
Individuals who plan to attend in person and need special assistance, 
such as sign language interpretation or other reasonable 
accommodations,

[[Page 40776]]

should notify the National Vaccine Program Office at the address/phone 
number listed above at least one week prior to the meeting. For those 
unable to attend in person, a live webcast will be available. More 
information on registration and accessing the webcast can be found at 
http://www.hhs.gov/nvpo/nvac/meetings/index.html.
    Members of the public will have the opportunity to provide comments 
at the NVAC meeting during the public comment periods designated on the 
agenda. Public comments made during the meeting will be limited to 
three minutes per person to ensure time is allotted for all those 
wishing to speak. Individuals are also welcome to submit their written 
comments. Written comments should not exceed three pages in length. 
Individuals submitting written comments should email their comments to 
the National Vaccine Program Office ([email protected]) at least five 
business days prior to the meeting.

    Dated: July 31, 2018.
Roula K. Sweis,
Chief of Management and Operations, National Vaccine Program Office.
[FR Doc. 2018-17618 Filed 8-15-18; 8:45 am]
 BILLING CODE 4150-44-P


Current View
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionNotice.
DatesThe meeting will be held on September 12 and 13, 2018. The meeting times and agenda will be posted on the NVAC website at http:// www.hhs.gov/nvpo/nvac/meetings/index.html as soon as they become available.
ContactAnn Aikin, Acting Designated Federal Officer, National Vaccine Program Office, U.S. Department of Health and Human Services, Room 715H, Hubert H. Humphrey Building, 200 Independence Avenue SW, Washington, DC 20201. Phone: (202) 690-5566; email: [email protected]
FR Citation83 FR 40775 

2024 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR